RETRACTED: Rheumatoid arthritis (RA) and cardiovascular disease

Publication date: Available online 1 August 2020Source: Autoimmunity ReviewsAuthor(s): Arnon Blum, Mohammad Adawi
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research

Related Links:

Authors: Khazzam M, Gee AO, Pearl M Abstract The Management of Glenohumeral Joint Osteoarthritis Evidence-Based Clinical Practice Guideline is based on a systematic review of published studies for the treatment of glenohumeral joint osteoarthritis. The purpose of this clinical practice guideline is to address the management of patients with glenohumeral joint osteoarthritis. It is not intended to address the management of glenohumeral joint arthritis from etiologies other than osteoarthritis (ie, rheumatoid arthritis, inflammatory arthritis, posttraumatic arthritis, osteonecrosis, rotator cuff tear arthroplasty, ca...
Source: The Journal of the American Academy of Orthopaedic Surgeons - Category: Orthopaedics Tags: J Am Acad Orthop Surg Source Type: research
CONCLUSIONS: . Although ADR data in the DREAM-RA registry were partly comparable with data in the SmPCs, RWD from this patient registry provided an added value to the currently available information on the incidences of ADRs associated with DMARDs in RA patients as described in SmPCs. PMID: 32990050 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Conditions:   Rheumatoid Arthritis;   Exercise;   Exercise Therapy Interventions:   Other: Aerobic Exercises;   Other: Resistive Exercises;   Other: Range of Motion Exercises Sponsor:   Sisli Hamidiye Etfal Training and Research Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.0c13261
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
Contributors : Vinod Krishna ; Sunil NagpalSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe study a new pathogenic, glycolytic PD1+ B cell population in sites of inflammation of patients with Rheumatoid Arthritis (RA).
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Nature Reviews Rheumatology, Published online: 30 September 2020; doi:10.1038/s41584-020-00521-xCardiac toxicity can be induced by hydroxychloroquine, especially when used in combination with azithromycin. Interest in hydroxychloroquine and azithromycin as potential therapies for COVID-19 has renewed concerns about the possible cardiovascular risk these drugs present to patients with rheumatoid arthritis.
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Source Type: research
ConclusionMedical management of patients with RA has reduced the need for THA, while postoperative medical and surgical management has improved some postoperative outcomes. Nevertheless, there remains room for further improvement to postoperative outcomes through RA-specific management.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
Tenascin-C (TNC) is a large multimodular glycoprotein of the extracellular matrix that consists of four distinct domains. Emerging evidence suggests that TNC may be involved in the pathogenesis of osteoarthritis (OA) and rheumatoid arthritis (RA). In this review, we summarize the current understanding of the role of TNC in cartilage and in synovial biology, across both OA and RA. TNC is expressed in association with the development of articular cartilage; the expression decreases during maturation of chondrocytes and disappears almost completely in adult articular cartilage. TNC expression is increased in diseased cartilag...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Arthritis | Cardiology | Cardiovascular | Heart | Rheumatoid Arthritis | Rheumatology